Literature DB >> 8835647

Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants.

P J Perry1.   

Abstract

The effectiveness of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) were contrasted in endogenous/melancholic depression. By reviewing Hamilton Depression Rating data from controlled trials, the data indicate that TCAs are consistently more effective than the SSRIs. Despite the wide use of SSRIs in the treatment of depression, it seems reasonable that clinicians subtype their depressed patients and treat melancholic patients first with a course of TCAs. For melancholic patients who have not responded to a SSRI, pharmacotherapeutic alternatives include (1) a TCA alone; (2) TCA augmentation of the SSRI, or (3) lithium augmentation of the SSRI.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8835647     DOI: 10.1016/0165-0327(96)00014-6

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  22 in total

1.  Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder.

Authors:  Gordon Parker; Max Fink; Edward Shorter; Michael Alan Taylor; Hagop Akiskal; German Berrios; Tom Bolwig; Walter A Brown; Bernard Carroll; David Healy; Donald F Klein; Athanasios Koukopoulos; Robert Michels; Joel Paris; Robert T Rubin; Robert Spitzer; Conrad Swartz
Journal:  Am J Psychiatry       Date:  2010-07       Impact factor: 18.112

2.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

Review 3.  Moving pharmacoepigenetics tools for depression toward clinical use.

Authors:  Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop
Journal:  J Affect Disord       Date:  2019-02-06       Impact factor: 4.839

4.  GABAergic control of depression-related brain states.

Authors:  Bernhard Luscher; Thomas Fuchs
Journal:  Adv Pharmacol       Date:  2015-01-14

5.  gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression.

Authors:  Qiuying Shen; Rachnanjali Lal; Beth A Luellen; John C Earnheart; Anne Milasincic Andrews; Bernhard Luscher
Journal:  Biol Psychiatry       Date:  2010-07-01       Impact factor: 13.382

6.  Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.

Authors:  R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin
Journal:  Psychol Med       Date:  2011-09-20       Impact factor: 7.723

Review 7.  Depression: the search for separable behaviors and circuits.

Authors:  Ryan J Post; Melissa R Warden
Journal:  Curr Opin Neurobiol       Date:  2018-03-09       Impact factor: 6.627

8.  Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Authors:  Tracy M Felton; Tommy B Kang; Stephan Hjorth; Sidney B Auerbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

9.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

Review 10.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.